Several clinical trials have been conducted to examine the efficacy of SGLT-2 inhibitors in patients with MASLD and T2DM, and the results has indicated that SGLT-2 inhibitors (canagliflozin, dapagliflozin or empagliflozin) significantly improves hepatic lipid deposition, liver enzyme levels and liver stiffness [61–65]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.